CorMedix Inc. CRMD 深 滬
等待開盤 04-01 09:30:00 美东时间
6.79
+0.220
+3.35%
華盛通- 最 高6.89
- 今 開6.61
- 成交量 123.73万股
- 最 低 6.60
- 昨 收 6.57
- 總市值 5.37亿
- 52周最高 17.43
- 市盈率 靜 3.34
- 換手率 1.57%
- 52周最低 6.125
- 委 比 32.99%
- 總股本 7905.04万
- 歷史最高 52.00
- 量 比 1.01
- 振 幅 4.41%
- 歷史最低 0.73
- 每 手 1
- 風險率 2.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.000 million-$320.000 million.
03-05 21:25
Cormedix Earnings Review: Q4 Summary
Cormedix (NASDAQ:CRMD) released its Q4 earnings on Thursday, March 5, 2026 at 0...
03-05 21:24
Update: Cormedix Q4 Adj. EPS $0.61 Misses $0.82 Estimate, Sales $128.600M Beat $127.022M Estimate
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.82 by 25.25 percent. This is a 177.27 percent increase over earnings of $0.22 per share from the
03-05 21:22
财报速睇 | CorMedix Inc. 2025财年Q4营收1.29亿美元，同比增长312.1%；归母净利润0.14亿美元，同比增长4.1%
华盛资讯3月5日讯，CorMedix Inc.公布2025财年Q4业绩，公司Q4营收1.29亿美元，同比增长312.1%，归母净利润0.14亿美元，同比增长4.1%。
03-05 21:04
Cormedix Sees Q1 Sales $300.000M-$320.000M vs $108.873M Est
Cormedix (NASDAQ:CRMD) sees Q1 sales of $300.000 million-$320.000 million vs $108.873 million analyst estimate.
03-05 20:51
CorMedix’s CRMD Q4 net revenue hits USD 128.6 million, up 312%
CorMedix’s CRMD Q4 net revenue hits USD 128.6 million, up 312% CorMedix (CRMD) reported Q4 2025 net revenue of USD 128.6 million, including USD 91.2 million from DefenCath sales and USD 37.4 million from the Melinta portfolio; total operating expenses were USD 48.2 million, up 182%. Q4 net income wa
03-05 20:30
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
CorMedix Inc. published an update to their financial calendar
CorMedix Inc. published an update to their financial calendar CorMedix Therapeutics (Nasdaq: CRMD) will report fourth-quarter and full-year 2025 financial results before the market opens on March 5, 2026, and will host a corporate update conference call the same day at 8:30 a.m. ET. The call will be
03-02 21:32
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix Therapeutics will release its financial results for Q4 and full year 2025 before the market opens on March 5, 2026, followed by a corporate update call at 8:30am ET. The company, which focuses on developing therapies for life-threatening conditions, commercializes products like DefenCath (taurolidine and heparin) for preventing catheter-related infections and a portfolio of anti-infective drugs acquired from Melinta Therapeutics. CorMedi...
03-02 13:30
CorMedix Inc. to Present at Major Healthcare Investor Conferences
CorMedix Inc. to Present at Major Healthcare Investor Conferences CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, will participate in several upcoming investor conferences in March 2026. The company’s senior man
02-12 21:31
